ExaWizards' (TYO:4259) wholly owned subsidiary, ExaMD, started a SAKIGAKE comprehensive evaluation consultation with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its AI-powered cognitive function diagnostic support app, according to a Friday filing with the Tokyo bourse.
The product is a software-as-a-medical-device that analyzes cognitive function from voice data collected via smartphones and other devices, it said.
Shares of ExaWizards rose nearly 1% in recent trade.